China Sky One Medical submits 26 new drugs for SFDA approval
September 11. INTERFAX-CHINA - China Sky One Medical Inc. has submitted 26 new drugs to the State Food and Drug Administration for production approval, a senior official from the company told Interfax on Sept. 11.
China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Amex: CSY), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), announced that it successfully developed 26 new drugs that are currently in clinical trials.
Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong"), a wholly-owned subsidiary of China Sky One Medical, recently completed research and development for the 26 new drugs, which have been submitted to the State Food and Drug Administration (SFDA) in the PRC for approval.
--Four drugs, including Cleaning suppositories, Tinidazole suppositories, Policresulen vaginal suppositories, and Aciclover gel are for the treatment of vaginits;
--Three drugs, including Chlorhexidine Gluconate, Cetylpyridinium Chloride and Compound Chlorhexidine, are gargles for the treatment of toothache;
--Three drugs, including Diclofenac Sodium Suppositories, Paediatric Ibuprofen suppositories and Musky cream, are for pain relief;
--Three drugs, including Hydroxybenzene gel, Podophyllotoxin Tincture and Nitrofurantoin suppositories, are anti-infectives;
--Two drugs, including Collunarium and Compound Naphazoline Spray, are for the treatment of rhinopathy;
--Two drugs, including Sulfasalazine suppositories and Sodium ferulate injection are for the treatment of cardiovascular disease;
--Methionine Vitamin B1 injection is for improving liver function;
--Doxofylline injection is for the treatment of asthma;
--Pantoprazole sodium injection is for the treatment of canker sores;
--Calcium Folinate injection is intended as an antidote for folic acid deficiency;
--Hydrastis suppositories are for the treatment of colds; and
--The final four drugs, including hemorrhoids gel, hemorrhoids liquids, chilblain cream and expectorant, are all externally used.
"We are excited about the potential for our new drugs currently in clinical trials and we believe that our advanced R&D capabilities will continue to help us expand our market share," said Mr. Yan-Qing Liu, Chairman, CEO and President of China Sky One Medical. "We estimate that the new drugs will account for a 30% increase in our 2009 revenues if production approval is received by the end of the year."
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a
Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
China Sky One Medical, Inc
http://www.skyonemedical.com